Orexo: Q2, Commercialisation model for DTx emerging - Redeye

Redeye maintains its positive view on Orexo after the Q2 report. While the impact on lost exclusivity for Zubsolv results in lower, but stable, pharma quarterly revenues, a viable commercialisation model for the digital therapies is taking shape and the company continues investing in innovation and targeted market outreach. We maintain our valuation at SEK 80 per share.

https://www.redeye.se/research/817139/orexo-q2-commercialisation-model-for-dtx-emerging?utm_source=finwire&utm_medium=RSS